Dr. Jeffrey Kopin, Chief Medical Officer for Northwestern Medicine Lake Forest Hospital, joins John Williams to talk about ...

GLP-1 drugs like Ozempic and Zepbound are great at promoting weight loss, but they also cause folks to lose muscle along with ...

Novo Nordisk had been providing Hims & Hers with the FDA-approved Wegovy, an injectable semaglutide used for weight loss ...

Below are a few more promising studies of weight-loss drugs. Combining bimagrumab, an investigational human monoclonal antibody that binds to and inhibits activin receptor type-2B, with semaglutide ...

In a statement on Monday, Amgen Inc. (NASDAQ:AMGN) announced that its phase 2 study of its weight loss drug candidate, ...

Combination therapy with a long-acting amylin analogue and a glucagon-like peptide-1 (GLP-1) receptor agonist results in ...

Full Phase 2 study results showed side effects that led people to stop treatment with MariTide, as well as weight loss ...

Strong efficacy and cardiovascular benefits should allow Novo to continue growing sales of GLP-1 therapies in diabetes. While Novo lost share to Eli Lilly's once-weekly Trulicity, Ozempic and Rybelsus ...

Trial finds weight loss drug taken monthly helps people lose 20% of body weight – but adverse GI events were ‘common’ - The ...

Novo Nordisk shares tumble 5.6% after ending Hims & Hers partnership and releasing disappointing CagriSema obesity drug trial ...

Novo Nordisk A/S scrapped a partnership with Hims & Hers Health Inc. after less than two months, saying the US company is ...

A new study finds that the diabetes drug liraglutide significantly reduced monthly migraine days in patients with obesity and ...